Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Funding Debate Reframed By GAO Reports On Strategic Planning

This article was originally published in The Pink Sheet Daily

Executive Summary

Republican senators argue reports show that FDA needs significant reform; discussion of Cures and User Fee legislation will now likely focus on what the plan should be.

You may also be interested in...



US FDA Progress Report Highlights Biomarkers, Continuous Manufacturing, Antibiotic Testing

Agency documents its regulatory science accomplishments to advance product development and manufacturing and ensure the safety and effectiveness of marketed products.

FDA's Information Security Fixes Expected To Be Completed Within A Year

GAO report prompts vigorous action – and some defensiveness – by the agency.

FDA's Beleaguered Criminal Investigations Unit Now Facing Congressional Scrutiny

After staff complain about becoming the 'Botox police,' a House committee is asking FDA for an update on two previous reports raising issues of management and morale in the Office of Criminal Investigations.

Related Content

Topics

UsernamePublicRestriction

Register

PS079514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel